Videos

Study results suggest that agonist stimulation of PPAR delta may be an effective therapeutic strategy to addressing dysfunctional metabolism in Alzheimer disease.

Haeberlein spoke about a number of topics in the Alzheimer space, including the progress that has been made and her excitement for the future.

The phase IIb/III study is scheduled to initiate enrollment of approximately 450 patients, randomized 1:1:1 to 2 different ANAVEX 2-73 doses or placebo.

The professor of psychiatry in neurology at the Gertrude H. Sergievsky Center at Columbia University Medical Center spoke about the possibility of using lithium for agitation in Alzheimer.

Higher doses of gantenerumab, a monoclonal antibody designed to bind to aggregated Aβ and remove beta plaques, will be investigated in phase III trials.

The senior lecturer in Clinical Pharmacy at Aston University talked about issues facing the medical community in treating those with dementia who have sleep problems.

The results conclude that treatment with crenezumab was associated with a consistent decrease in Aβ oligomer levels in the CSF.

Is there a correlation between sickle cell trait and incidence of ischemic stroke among African-Americans?

This technology offers a non-invasive, image-guided and reversible approach to blood-brain barrier, suggesting the possibility of its use in Alzheimer disease.

The senior lecturer in Clinical Pharmacy at Aston University spoke about the findings of the ZED study, which looked into the use of hypnotic z-drugs.

ANAVEX 2-73 is being studied as the first potential precision medicine biomarker-guided, targeted therapeutic in Alzheimer disease.

The director of the University of Rochester Alzheimer's Disease Care, Research and Education Program spoke about the need to rethink trial design and Alzheimer neuropsychiatric symptom management.

This is the first large late-stage clinical trial to further support the amyloid hypothesis.

The SPRINT MIND trial found a statistically significant lower rate of new cases of mild cognitive impairment in the intensive treatment group.

The psychiatry and pharmacology professor spoke about the results from the first clinical trial that showed that a cannabinoid can decrease agitation in Alzheimer disease.

Efficacy was demonstrated in this patient population at the primary endpoint of 6 weeks, especially in those with more severe baseline NPI-NH-PS.

Data from an interim analysis of the lumateperone large phase III clinical trial for agitation in subjects with dementia is expected by the end of 2018.

These guidelines will provide primary clinicians and the specialist community an important new tool to more accurately diagnose patients.

A prospective cohort study of patients offered amyloid PET as part of their dementia work-up. The results here.

The FDA has approved a new drug for the prevention of migraines. Will the injectable treatment help reduce the number of days of migraine headaches?

How effective is the telemedicine versus telephonic approach in acute care?

An update on the prevalence and features of demoralization in patients with PD.

5 key facts about cerebral microbleeds and risk of future cognitive impairment.

5 important facts from a recent double-blind, randomized phase 3 study about siponimod in SPMS.

The group medical director of neuroscience at Genentech discussed the history of a well-known therapy for multiple sclerosis: ocrelizumab (Ocrevus).

The associate professor of clinical neurology spoke about the need to understand modifiable social and cultural factors that could impact disease severity and progression.

The clinical director of the Anti-NMDA Receptor Encephalitis Foundation spoke about the insidiousness of AD and the need for diagnosis earlier in disease progression.

The UC Health professor of neurology argued that with the current view on Parkinson disease, the field is missing the mark for disease-modifying interventions.

The chief medical officer and chief operating officer of Brainstorm Cell Therapeutics spoke about a host of topics related to the treatment of amyotrophic lateral sclerosis.

A study examines a possible link between lifestyle and onset of PD.